British Journal of Hospital Medicine,
Journal Year:
2024,
Volume and Issue:
85(11), P. 1 - 13
Published: Nov. 30, 2024
Aims/Background
Primary
hypercholesterolemia
(PHC)
is
a
major
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
Although
the
fact
that
statins
effectively
lower
low-density
lipoprotein
cholesterol
(LDL-C)
levels,
some
patients
fail
to
achieve
target
LDL-C
levels
and
continue
have
high
of
disease.
This
study
aims
evaluate
clinical
efficacy
safety
ezetimibe
combined
with
rosuvastatin
in
PHC.
Methods
retrospectively
examined
101
PHC
who
received
at
cardiology
department
Jilin
Province
FAW
General
Hospital,
between
2021
2024.
Patients
were
divided
into
observation
(ezetimibe
rosuvastatin,
n
=
45)
control
(rosuvastatin,
66)
groups
accordance
their
treatment
regimens.
Data
sourced
from
hospital's
electronic
health
records
system,
statistical
analysis
was
performed
by
using
SPSS
25.0
software
(IBM
Corporation,
Armonk,
NY,
USA).
Results
Baseline
characteristics
similar
two
groups.
After
12
weeks
treatment,
reduction
group
(–0.373
[–0.427,
–0.348])
greater
than
(–0.240
[–0.318,
–0.222],
p
<
0.001).
The
percentage
changes
total
(TC),
triglyceride
(TG),
high-density
(HDL-C)
significantly
better
(TC:
–0.230
[–0.302,
–0.144],
TG:
–0.292
[–0.333,
–0.237],
HDL-C:
0.081
[0.067,
0.111])
–0.127
[–0.158,
–0.119],
–0.082
[–0.101,
–0.067],
0.000
[–0.163,
0.133]
0.001,
0.011,
respectively).
Regarding
drug
safety,
incidence
adverse
events
comparable
(11.10%
vs.
12.10%,
0.871).
Conclusion
combination
demonstrates
superior
lipid-lowering
good
inadequately
controlled
statin
therapy,
providing
an
effective
alternative
option.
Further
large-scale,
multicenter
randomized
trials
are
warranted
confirm
its
long-term
safety.
European Journal of Clinical Investigation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 6, 2024
Abstract
Background
Maintaining
low
concentrations
of
plasma
low‐density
lipoprotein
cholesterol
(LDLc)
over
time
decreases
the
number
LDL
particles
trapped
within
artery
wall,
slows
progression
atherosclerosis
and
delays
age
at
which
mature
atherosclerotic
plaques
develop.
This
substantially
reduces
lifetime
risk
cardiovascular
disease
(ASCVD)
events.
In
this
context,
plaque
development
vulnerability
result
not
only
from
lipid
accumulation
but
also
inflammation.
Results
Changes
in
composition
immune
cells,
including
macrophages,
dendritic
T
B
mast
cells
neutrophils,
along
with
altered
cytokine
chemokine
release,
disrupt
equilibrium
between
inflammation
anti‐inflammatory
mechanisms
sites.
Considering
that
it
is
a
competition
LDLc
inflammation,
instead
they
are
partners
crime,
present
narrative
review
aims
to
give
an
overview
main
inflammatory
molecular
pathways
linked
raised
describe
impact
lipid‐lowering
approaches
on
burden.
Although
remarkable
changes
driven
by
most
recent
lowering
combinations,
relative
reduction
C‐reactive
protein
appears
be
independent
magnitude
lowering.
Conclusion
Identifying
clinical
biomarkers
(e.g.
interleukin‐6)
possible
targets
for
therapy
holds
promise
monitoring
reducing
ASCVD
burden
suitable
patients.
Atherosclerosis Plus,
Journal Year:
2024,
Volume and Issue:
59, P. 25 - 31
Published: Dec. 12, 2024
Pharmacological
inhibition
of
Proprotein
Convertase
Subtilisin/Kexin
9
(PCSK9)
have
been
firmly
established
to
be
an
effective
approach
reduce
low-density
lipoprotein
(LDL)
cholesterol
levels
and
cardiovascular
events.
Subcutaneous
administration
monoclonal
antibodies
(evolocumab
alirocumab)
every
2
or
4
weeks
determined
a
60
%
reduction
LDL
levels,
while
the
GalNac-siRNA
anti
PCSK9
(inclisiran)
provided
lipid
lowering
activity
(-50
%)
after
initial
subcutaneous
dose,
repeated
3
months
followed
by
maintenance
dose
6
months.
Although
these
two
approaches
potentiality
bring
majority
patients
at
high
very-high
risk
appropriate
targets,
their
cost
represent
strong
limitation
for
large-scale
use.
These
problems
could
overcome
development
small
chemical
molecules
as
oral
therapy
controlling
hypercholesterolemia.
In
present
review,
we
summarized
pharmacological
properties
that
are
currently
under
clinical
(DC371739,
CVI-LM001,
AZD0780),
including
mimetic
peptides
enlicitide
decanoate
(MK-0616)
NNC0385-0434.
Aktuelle Kardiologie,
Journal Year:
2025,
Volume and Issue:
14(02), P. 129 - 135
Published: April 1, 2025
Zusammenfassung
Die
aktuelle
Leitlinie
der
ESC
(European
Society
of
Cardiology)
zum
chronischen
Koronarsyndrom
(CCS)
bringt
einige
Neuerungen
in
medikamentösen
Therapie
von
CCS-Patienten.
Diese
betreffen
die
antithrombotischen,
lipidsenkenden,
metabolischen,
antihypertensiven
sowie
antiinflammatorischen
Grundpfeiler
Therapie.
Neben
neuen
Empfehlungen
für
eine
individuelle
antithrombotische
wird
erstmalig
Bedeutung
einer
Medikation
bei
bestimmten
CCS-Patienten
zur
Reduktion
des
residuellen
Risikos
berücksichtigt.
Es
werden
zudem
neue
Konzepte
antimetabolischen
Verbesserung
kardiovaskulären
Outcomes
vorgestellt.
Optimierung
Therapieoptionen
Behandlung
Risikofaktoren
Kombination
mit
modernen
Thrombozytenaggregationshemmung
würde
zu
wirksamen
und
personalisierten
Präventionsstrategien
führen.
Clinical and Preventive Medicine,
Journal Year:
2025,
Volume and Issue:
2, P. 152 - 161
Published: April 17, 2025
Aim.
To
conduct
a
generalization
of
scientific
research
on
the
history
use
medications
for
correction
dyslipidemia
in
clinical
practice.
Materials
and
methods.
The
analysis
articles,
guidelines
recommendations
justification
implementation
appointment
hypolipidemic
drugs
treatment
prevention
cardiovascular
diseases
(CVD)
was
carried
out.
methods
used
were:
systematic
approach,
bibliosemantic,
analytical.
Results.
Hypotheses
regarding
role
hypercholesterolemia
development
atherosclerotic
lesions
system
were
proposed
as
early
second
half
19th
century,
approaches
need
to
correct
substantiated
only
with
introduction
concept
risk
factors
20th
century.
However,
it
took
almost
two
decades
CVD
into
first
pharmacological
drug
that
began
be
practice
nicotinic
acid
(niacin).
Bile
sequestrants
(cholestyramine,
colestipol,
colesevelam)
became
group,
fibrates
(fenofibrate,
bezafibrate,
gemfibrozil,
ciprofibrate)
third
group
therapy
drugs.
Later,
these
gave
way
statins,
whose
effectiveness
higher
safety
profile
better.
Statin
is
generally
well
tolerated
adverse
reactions
occur
less
than
5%
randomized
trials.
At
current
stage,
statins
remain
first-line
lipid
metabolism.
evidence
base
significant,
results
trials
have
demonstrated
this
secondary
primary
CVD.
Since
end
90s
there
has
been
steady
increase
prescription
Сonclusions.
Medications
since
Niacin,
fibrates,
bile
now
replaced
by
which
Archives of Medical Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 6, 2024
Coronary
artery
disease
(CAD)
is
the
most
common
cause
of
mortality
among
adults
worldwide.
In
prognostic
risk
stratification
these
patients,
crucial
determinants
are
lumen
stenosis,
total
volume
and
composition
plaque.
Considering
that
myocardial
infarctions
due
to
non-obstructive
plaques
or
associated
with
high-risk
features,
plaque
can
serve
as
an
independent
predictor
cardiac
outcomes.
Conversely,
although
a
tight
relationship
stands
between
ischemia
CAD
severity,
assessment
degree
ischemia,
surrogate
marker
coronary
burden,
remains
controversial
issue.
Thus,
aim
this
narrative
review
discuss
usefulness
imaging
methodologies
differentiate
vs
burden
in
clinical
practice.
New
diagnostic
tools
evaluate
extent
atheromatous
could
help
tailoring
personalized
therapeutic
approach.
